E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
High grade serous ovarian cancer |
|
E.1.1.1 | Medical condition in easily understood language |
|
E.1.1.2 | Therapeutic area | Diseases [C] - Cancer [C04] |
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 20.0 |
E.1.2 | Level | PT |
E.1.2 | Classification code | 10033128 |
E.1.2 | Term | Ovarian cancer |
E.1.2 | System Organ Class | 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) |
|
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
Primary in Pivotal Cohort (UPLIFT): Determine the confirmed investigator-assessed objective response rate of XMT-1536 (upifitamab rilsodotin) at a starting dose level of 36 mg/m2 q4wk capped at 2.2 m2 in patients with higher (TPS ≥75) sodium-dependent phosphate transport protein 2b (NaPi2b) expressing platinum-resistant high-grade serous ovarian cancer (HGSOC), including cancers of ovarian, fallopian tube or primary peritoneal origin) |
|
E.2.2 | Secondary objectives of the trial |
Secondary in UPLIFT: - Assess confirmed investigator-assessed objective response rate of XMT-1536 regardless of NaPi2b expression. - Assess confirmed objective response rate by indep radiology review (IRR) for patients with high (TPS =75) NaPi2b and overall. - Assess duration of objective response (DOR) in patients who achieve a response. - Assess incidence and severity of adverse events.
|
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
For Dose Escalation, Expansion and Uplift 1. Females and males, aged ≥18 years old 2. ECOG performance status 0 or 1 3. Measurable disease as per RECIST, version 1.1 4. Resolution of all acute toxic effects of prior therapy or surgical procedures to ≤Grade 1 (except alopecia, stable immune-related toxicity such as hypothyroidism on hormone replacement, adrenal insufficiency on ≤10 mg daily [prednisone] (or equivalent) chronic Grade 2 peripheral sensory neuropathy after prior taxane therapy). 5. Cardiac left ventricular ejection fraction (LVEF) ≥50% or ≥ the institution’s lower limit of normal by either Echo or MUGA scan 6. Adequate organ function as defined by the following criteria: a. Absolute neutrophil count (ANC) ≥1500 cells/mm3 b. Platelet count ≥100,000/mm3 c. Hemoglobin ≥9 g/dL d. In patients not on anticoagulation therapy: INR, activated partial thromboplastin time (aPTT), and prothrombin time (PT) all within 1.2 times the institutional upper limit of normal (ULN) in the absence of any other indicator of liver dysfunction. Patients on anticoagulants are allowed if their relevant laboratory values are within the therapeutic window. e. Estimated glomerular filtration rate (GFR) ≥45 mL/min f. Total bilirubin ≤ULN Patients with asymptomatic elevations in unconjugated bilirubin due to Gilbert syndrome or stable chronic hemolytic anemia may be eligible after discussion with the Sponsor Medical Monitor. 7. Aspartate aminotransferase (AST or SGOT) and alanine aminotransferase (ALT or SGPT) ≤1.5 times the institutional ULN. 8. Albumin ≥3.0 g/dL 9. Female participants of child-bearing potential must use a highly effective non-hormonal form of contraception for the duration of study drug administration and for at least 6 months after the last dose of study drug. Please see Appendix 7 of the Protocol for examples of non-hormonal highly effective contraceptive methods. 10. Male study participants must use barrier contraception (condoms) for the duration of study drug and for at least 6 months after the last dose of study drug. The WOCBP partners of male study participants must use highly effective contraception for the duration of study drug and for at least 6 months after the last dose of study drug 11. Able to provide informed consent for UPLIFT 1. Histological diagnosis of high grade serous ovarian cancer, which includes fallopian tube, or primary peritoneal cancer, that is metastatic or recurrent 2. Platinum-resistant disease a. Patients who have only had 1 line of platinum-based therapy must have received at least 4 cycles of platinum, must have had a response [complete response/remission (CR) or partial response/remission (PR)], and then progressed between 3 months and ≤ 6 months after the date of the last dose of platinum b. Patients who have received 2 to 4 lines of prior therapy must have received at least 4 cycles of platinum and then progressed within 6 months after the date of the last dose of platinum 3. One to 4 prior lines of systemic therapy for ovarian cancer a. Prior treatment with bevacizumab is required for patients with 1 to 2 prior lines of therapy. b. Definitions for prior lines of therapy: i. Adjuvant ± neoadjuvant considered one line of therapy as long as they are the same regimens (e.g., platinum/taxane for 4 cycles before surgery followed by platinum/taxane for 4 cycles after surgery) ii. Maintenance therapy (e.g., bevacizumab, PARPi, endocrine therapy) will be considered as part of the preceding line of therapy (i.e., not counted independently) iii. Therapy given for only 1 cycle and changed due to toxicity in the absence of progression will be considered as part of the same line (i.e., not counted independently); therapy given for 2 or more cycles will be counted as a new line iv. Hormonal therapy (e.g., tamoxifen, letrozole) will be counted as a separate line of therapy unless it was given as maintenance 4. Patients must be willing to provide an archival tumor tissue block or slides or if not available, undergo procedure to obtain a new tumor biopsy using a low-risk, medically routine procedure |
|
E.4 | Principal exclusion criteria |
For Dose Escalation, Expansion and Uplift 1. Major surgery within 28 days of starting study treatment, systemic anti-cancer therapy within the lesser of 28 days or 5 half-lives of the prior therapy before starting study treatment (14 days or 5 half-lives for small molecule targeted therapy), or recent radiation therapy with unresolved toxicity or within a time window of potential toxicity (consultation with the Sponsor Medical Monitor is recommended). 2. Patients with untreated CNS metastases (including new and progressive brain metastases), history of leptomeningeal metastasis or carcinomatous meningitis. a. Patients are eligible if CNS metastases are adequately treated and patients are neurologically stable for at least 2 weeks prior to enrollment. b. In addition, patients must be either off corticosteroids, or on a stable/decreasing dose of ≤ 10 mg daily prednisone (or equivalent). Anticonvulsants are allowed except for those drugs associated with liver toxicity. 3. Untreated known human immunodeficiency virus (HIV), hepatitis B virus (HBV), or hepatitis C virus (HCV). In addition, negative serology is required during screening (baseline) for HBV and HCV: a. HBV: Patients with serologic evidence of chronic HBV infection should have an HBV viral load below the limit of quantification to be eligible. b. HCV: Patients with a history of HCV infection should have completed curative antiviral treatment and HCV viral load below the limit of quantification. c. HIV: screening for HIV is not required except if mandated by local regulations or indicated based on clinical assessment. 4. Current severe, uncontrolled systemic disease (e.g., clinically significant cardiovascular, pulmonary, or metabolic disease) or intercurrent illness that could risk of adverse events, whether or not potentially related to study treatment (in unclear cases, consultation with the Medical Monitor is recommended). Further, patients are excluded with the following characteristics: a. A marked baseline prolongation of QT/QTc interval using Frederica's QT correction formula. b. A history of additional risk factors for Torsade's de Pointes (e.g., heart failure, hypokalemia, family history of Long QT Syndrome). c. The use of concomitant medications that prolong the QT/QTc interval will be reviewed first with the Sponsor Medical Monitor. 5. History of cirrhosis, hepatic fibrosis, esophageal or gastric varices, or other clinically significant liver disease. FibroScan testing may be required for patients with a history of chronic liver disease, e.g., fatty liver. Testing beyond laboratory studies otherwise defined in the eligibility criteria, to diagnose potentially clinically significant liver disease based on risk factors such as hepatic steatosis or history of excessive alcohol intake, will be based on clinical judgement of the investigator. 6. Patients cannot receive drugs associated with hepatotoxicity concurrent with XMT-1536 administration. Patients may receive acetaminophen/paracetamol for a limited time but at a total daily dose of ≤2 g per day. Use of NSAIDs or steroids for treatment of fever is encouraged. 7. Current use of either constant or intermittent supplementary oxygen therapy. 8. History of or suspected pneumonitis, or interstitial lung disease. 9. Oxygen saturation on room air <93%. 10. Pregnant or nursing women. 11.Diagnosis of additional malignancy that progressed or required active treatment within at least 2 years , except for adequately treated basal cell or squamous cell skin cancer, or carcinoma in situ of the breast or of the cervix 12. Active corneal disease, or history of corneal disease within 12 months prior to enrollment. 13. Use of strong CYP450 inhibitors 3A inhibitors or inducers that cannot be discontinued while receiving study treatment.. 14. Known sensitivity to any of the study medications, or components thereof, or a history of drug or other allergy that, in the opinion of the investigator or Medical Monitor, contraindicates their participation. 15. In the Czech Republic, patients cannot be enrolled if they have received a live/attenuated vaccine within 30 days of study entry or if they plan to receive a live/attenuated vaccine while on treatment through 90 days post the last dose of study medication
Ovarian Cancer Exclusion Criteria for UPLIFT – Cohort 1. Low-grade, clear cell, endometrioid, mucinous, carcinosarcoma, germ-cell, mixed histology, or stromal tumors 2. Prior treatment with mirvetuximab soravtansine or another ADC containing an antitubulin payload 3. Primary platinum-resistant disease, defined by a lack of response or by progression within 3 months after completing front-line, platinum-containing therapy. 4. Participation in DES or EXP segments of this study |
|
E.5 End points |
E.5.1 | Primary end point(s) |
For UPLIFT: Objective Response Rate (ORR) in the ITT-Higher NaPi2b population
|
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
For UPLIFT: - Derived at the end of the study using a composite of RECIST evaluations that are compared to each patient’s baseline measurement and subsequent post-baseline measurements |
|
E.5.2 | Secondary end point(s) |
For UPLIFT: Confirmed investigator-assessed ORR in the entire ITT population ORR by IRR in the ITT-Higher NaPi2b population; ORR by IRR in the entire ITT population DOR in the ITT-Higher NaPi2b population DOR in the entire ITT population Safety and tolerability measures |
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
- for Confirmed investigator-assessed ORR in the entire ITT population, ORR by IRR in the ITT-Higher NaPi2b population and ORR by IRR in the entire population, the timepoint is: derived at the end of the study using a composite of RECIST evaluations that are compared to each patient’s baseline measurement and subsequent post-baseline measurements - for DOR in the ITT-Higher NaPi2b population and DOR in the entire ITT population, the timepoint is: at the end of the study - for Safety and tolerability, the timepoint is: from Day 1 to the end of the study |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | No |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | No |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | Yes |
E.7.3 | Therapeutic confirmatory (Phase III) | No |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | No |
E.8.1.1 | Randomised | No |
E.8.1.2 | Open | Yes |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | No |
E.8.1.5 | Parallel group | No |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | No |
E.8.2.3 | Other | No |
E.8.3 |
The trial involves single site in the Member State concerned
| No |
E.8.4 | The trial involves multiple sites in the Member State concerned | Yes |
E.8.4.1 | Number of sites anticipated in Member State concerned | 5 |
E.8.5 | The trial involves multiple Member States | Yes |
E.8.5.1 | Number of sites anticipated in the EEA | 80 |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | Yes |
E.8.6.2 | Trial being conducted completely outside of the EEA | No |
E.8.6.3 | If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned |
Australia |
Canada |
New Zealand |
United States |
Russian Federation |
Belgium |
Bulgaria |
Czechia |
Denmark |
Finland |
France |
Hungary |
Italy |
Lithuania |
Norway |
Poland |
Spain |
Sweden |
United Kingdom |
|
E.8.7 | Trial has a data monitoring committee | No |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
Subjects will have an End of Treatment Visit (LSLV) and thereafter will be followed for survival via telephone calls every 3 months. |
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 3 |
E.8.9.1 | In the Member State concerned months | 9 |
E.8.9.1 | In the Member State concerned days | 30 |
E.8.9.2 | In all countries concerned by the trial years | 7 |
E.8.9.2 | In all countries concerned by the trial months | 0 |
E.8.9.2 | In all countries concerned by the trial days | 20 |